We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Of the task force members, Wyden noted, 15 are subject to reporting requirements under the CMS Open Payments system, a database that documents drug and devicemakers’ payments to physicians and teaching hospitals. Read More
“The nefarious tactics that drug companies use to influence state Medicaid programs’ drug coverage decisions are dishonest and disturbing,” said Booker. Read More
The generic drugmakers at the center of a multistate antitrust suit asked a Philadelphia federal court to impose a gag order on investigators after a Washington Post story published earlier this month revealed key details about the case. Read More
A federal jury on Tuesday convicted a former physician assistant of participating in a conspiracy to prescribe Insys’ potent fentanyl spray in exchange for kickbacks. Read More
Attorneys for the U.S. Public Interest Research Group and for two groups of independent pharmacists’ filed petitions asking Leon to hear their arguments against the merger. Read More
Former governor of Tennessee, Alexander was first elected to the Senate in 2002. In his farewell statement on Monday, he took credit for anti-opioids legislation signed by President Trump in October and for writing the 21st Century Cures Act. Read More
Retiring Sen. Orrin Hatch (R-Utah) urged his Republican colleagues not to support the White House drug pricing plan, claiming it oversteps HHS authority. Read More
Sen. Ron Wyden (D-Ore.), the ranking member of the Senate Finance Committee, is seeking an explanation for the steadily growing cost of Pfizer’s blockbuster drug Lyrica. Read More
A federal judge on Wednesday issued a preliminary injunction against a New York state law that imposed surcharges on opioid manufacturers and distributors. Read More
The agency’s proposal would lead to a small category of biological products currently regulated as drugs — such as insulin and human growth hormone —to be regulated as biosimilars under the Biologics Price Competition and Innovation Act (BPCIA) and would “enable, for the first time, products that are biosimilar to, or interchangeable with, these products to come to market,” Gottlieb said. Read More
Sen. Orrin Hatch (R-Utah) and two colleagues have introduced a set of proposed reforms that they say will bring clarity and prevent arbitrage by making patent challengers choose one route or the other. Read More